RxDoctor Payments Data

Joel Griffith, MD

Psychiatry · Bloomington, INNPI 1194747618

Payments from drug & device makers

$1,050in general payments, 2019–2025

Across 60 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$187
  • E.r. Squibb & Sons, L.L.C.$125
  • Indivior Inc.$93
  • Otsuka America Pharmaceutical, Inc.$86
  • Neurocrine Biosciences, Inc.$79
  • Supernus Pharmaceuticals, Inc.$70
  • plus $410 from 12 others

What the payments were for

  • Food & beverage$1,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,050 in reported general payments places this provider in the 65th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$2,177
Medicare patients
18
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate140$496,911
IngrezzaValbenazine Tosylate29$234,146
AustedoDeutetrabenazine30$150,380
Invega TrinzaPaliperidone Palmitate14$134,076
AristadaAripiprazole Lauroxil16$50,818
VraylarCariprazine Hcl31$45,166
Paliperidone ErPaliperidone70$17,340
Lurasidone Hcl40$16,921
Asenapine Maleate52$15,515
TrintellixVortioxetine Hydrobromide16$10,849
LinzessLinaclotide18$9,736
Desvenlafaxine Succinate ErDesvenlafaxine Succinate82$7,712
Clozapine140$7,662
Olanzapine109$6,280
Divalproex Sodium ErDivalproex Sodium68$5,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$58$630,987154 claims
Neurocrine Biosciences, Inc.Ingrezza$79$234,14629 claims
Teva Pharmaceuticals USA, Inc.Austedo$26$150,38030 claims
AbbVieVraylar, Linzess$60$54,90249 claims
Alkermes, Inc.Aristada$11$50,81816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$26$15,00327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Bloomington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →